GSK joins forces with CureVac to manufacture its Covid-19 vaccine — and to develop another
Vaccine production giant GlaxoSmithKline announced Wednesday that it would partner with German biotech CureVac to help manufacture its messenger RNA vaccine — and jointly develop a separate vaccine to target new variants of the SARS-CoV-2 virus.
The next-generation vaccine may be a multivalent, meaning it would protect against several strains of the virus. The companies hope to be able to introduce an updated vaccine in 2022, pending approval from regulatory agencies.
